Poor
Misaligned
Patient Risk:
Moderate
Summary
Most statements about interactions and cytochrome P450 inhibition are not supported as written by the provided label excerpts, and some claims are overly specific (e.g., pain medication increase/impact on effectiveness and “inhibits CYP activity”); the label excerpts provided only support that strong CYP3A4 inhibitors can increase atorvastatin plasma concentrations and that concurrent statin risks (e.g., myopathy) increase with certain drugs.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is a medication used to lower cholesterol levels.
Section 1.2 (Hypeerlipidemia) indicates LIPITOR is used to reduce lipid parameters (e.g., total-C, LDL-C, apo B, TG) and increase HDL-C as adjunct to diet.
Lipitor can interact with pain medication.
Section 7 (Drug Interactions) and Section 5.1/7 general interaction language are provided, but the label excerpts do not specifically mention “pain medication.” This statement is only broadly supported as an interaction claim (not specific to pain drugs).
Unsupported Statements
Lipitor works by inhibiting the production of cholesterol in the liver, reducing the amount of cholesterol in the blood.
No mechanism statement is included in the provided label excerpts.
Lipitor can increase the levels of certain pain medications in the blood.
The provided label excerpts state that concomitant administration of strong CYP3A4 inhibitors can increase plasma concentrations of atorvastatin, not that atorvastatin increases pain medication levels.
This increase in pain medication levels can lead to increased side effects such as drowsiness, dizziness, and nausea.
No label excerpt provided links atorvastatin to increased levels of pain medications or to these specific side effects in that interaction context.
The effectiveness of pain medication can be significantly impacted by Lipitor.
No provided label excerpt addresses changes in analgesic effectiveness due to atorvastatin.
Patients taking Lipitor may experience reduced pain relief.
No provided label excerpt addresses pain relief reduction.
Lipitor (atorvastatin) is a substrate of cytochrome P450 enzymes.
The provided excerpts indicate metabolism by CYP3A4 (Section 7.1), but this substrate phrasing is not explicitly stated as “substrate” in the provided text; support is at best indirect.
Lipitor can inhibit cytochrome P450 enzyme activity.
No provided label excerpt states that atorvastatin inhibits CYP activity.
Inhibition of cytochrome P450 enzymes can lead to increased levels of pain medication in the blood.
No provided label excerpt supports atorvastatin inhibiting CYP enzymes or increasing other drugs’ plasma levels via CYP inhibition.
Lipitor can interact with over 100 medications, including many pain medications.
No provided label excerpt supports a quantitative count (“over 100”) or specifically enumerates pain medications.
The article states that it is generally not recommended to take Lipitor and ibuprofen together because they can interact and increase the risk of side effects.
The provided label excerpts do not mention ibuprofen or provide guidance that atorvastatin and ibuprofen should not be co-administered.
A patient taking Lipitor and ibuprofen reported increased side effects including stomach upset and dizziness.
No provided label excerpt includes this specific case report or links ibuprofen co-administration with those reported effects.
Contradictions
Important Omissions
If discussing CYP-mediated interactions, the label excerpts provided describe that atorvastatin is metabolized by CYP3A4 and that concomitant strong CYP3A4 inhibitors can increase atorvastatin plasma concentrations; the response did not align the direction of interaction with the label text.
Importance:
High
The label excerpts provided discuss increased risk of myopathy/rhabdomyolysis with certain concomitant drugs (e.g., cyclosporine/strong CYP3A4 inhibitors), but the response focused on drowsiness/dizziness/nausea from increased pain medication levels.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response asserts specific interaction directions and consequences (increased pain medication levels, reduced pain relief, specific side effects) without support from the provided labeling excerpts, which could mislead about interaction risk and management.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Misaligned
Primary Issue
Interaction claims are misaligned with provided label excerpts: the label excerpts support increased atorvastatin concentrations with strong CYP3A4 inhibitors, not increased pain-medication concentrations due to atorvastatin CYP inhibition; no label support is provided for ibuprofen-specific recommendations or pain-relief impairment.
Suggested Improvement
Restrict interaction discussion to what the provided label excerpts state (e.g., atorvastatin metabolized by CYP3A4; strong CYP3A4 inhibitors can increase atorvastatin plasma concentrations; concomitant drugs can increase risk of myopathy/rhabdomyolysis). Remove or rewrite unsupported specifics about pain medication level increases, analgesic effectiveness reduction, and ibuprofen co-administration.